Live
Funding 2 min read

Estonian business angels first to back LifeGlue, the Finnish supplier behind lab-grown human tissues

Finnish biotech company LifeGlue Technologies has raised €705,000 in seed funding, with the Estonian Business Angels Network EstBAN as the initial investor. The funding will support the company in developing animal-free materials for lab-grown human tissues.

Image: EstBAN

Finnish biotech company LifeGlue Technologies has successfully raised €705,000 in seed funding, marking a significant milestone in its mission to deliver animal-free material that enables companies and research groups globally to grow human tissues in laboratory settings. The Estonian Business Angels Network (EstBAN) took the lead as the first investor in this round, which was announced during sTARTUp Day held in Tartu.

LifeGlue's innovative technology promises to transform the landscape of biomedical research and regenerative medicine. The funds are expected to catalyze further advancements in their product capabilities, potentially expanding their applications across various sectors.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

EstBAN Open source

Estonian business angels first to back LifeGlue, the Finnish supplier behind lab-grown human tissues

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

No reviewed connections found in the current history window.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority7 / 10

Priority

Source coverageSingle-source report

Single-source report

ConfidenceLimited

42 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • fresh coverage
  • editorial priority

Source monitoring: 99% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.